Barclays’s ImmunityBio IBRX Stock Holding History

Barclays’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.45M	Buy	+189,600	New	+$1.3M	﹤0.01%	2534
2025 Q3	–	Sell	-120,000	Closed	-$317K	–	5599
2025 Q2	$317K	Buy	+120,000	New	+$323K	﹤0.01%	4021
2024 Q2	–	Sell	-197,300	Closed	-$1.06M	–	5067
2024 Q1	$1.06M	Buy	+197,300	New	+$893K	﹤0.01%	3074

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Barclays's IBRX Position: Q1 2026 in Review

Barclays reduced its ImmunityBio (IBRX) stake by 23% in Q1 2026, selling an estimated $3.79M and leaving 1,890,100 shares worth $14.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1249.

Barclays first reported a position in IBRX in Q4 2015 and has held it in 38 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Barclays held 1,890,100 shares of ImmunityBio worth $14.5M as of Q1 2026.
Barclays sold 554,063 ImmunityBio shares in Q1 2026, an estimated $3.79M.
ImmunityBio made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1249 holding.
Barclays first reported a position in ImmunityBio in Q4 2015 and has held it in 38 quarters since.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.